CRISPR Therapeutics AG (NASDAQ:CRSP) Director Bradley J. Phd Bolzon sold 20,375 shares of the firm's stock in a transaction that occurred on Monday, June 28th. The stock was sold at an average price of $152.48, for a total transaction of $3,106,780.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Shares of NASDAQ:CRSP traded up $11.40 during trading on Wednesday, reaching $161.89. The company had a trading volume of 5,828,852 shares, compared to its average volume of 1,881,453. The company has a fifty day moving average price of $121.31. The stock has a market cap of $12.27 billion, a PE ratio of -28.39 and a beta of 2.26. CRISPR Therapeutics AG has a 12 month low of $74.00 and a 12 month high of $220.20.
CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Monday, April 26th. The company reported ($1.51) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.47) by ($0.04). CRISPR Therapeutics had a negative net margin of 35,630.97% and a negative return on equity of 27.42%. The business had revenue of $0.54 million for the quarter, compared to the consensus estimate of $4.99 million. On average, equities analysts anticipate that CRISPR Therapeutics AG will post 0.66 EPS for the current fiscal year.
Several hedge funds have recently added to or reduced their stakes in the stock. Nikko Asset Management Americas Inc. grew its holdings in shares of CRISPR Therapeutics by 3.8% during the 4th quarter. Nikko Asset Management Americas Inc. now owns 3,836,823 shares of the company's stock valued at $587,456,000 after purchasing an additional 139,156 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of CRISPR Therapeutics by 8.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,774,436 shares of the company's stock worth $271,684,000 after purchasing an additional 143,504 shares during the period. BlackRock Inc. lifted its position in shares of CRISPR Therapeutics by 10.0% in the 1st quarter. BlackRock Inc. now owns 1,290,335 shares of the company's stock worth $157,226,000 after purchasing an additional 117,076 shares during the period. Bellevue Group AG lifted its position in shares of CRISPR Therapeutics by 7.6% in the 1st quarter. Bellevue Group AG now owns 978,384 shares of the company's stock worth $119,216,000 after purchasing an additional 68,700 shares during the period. Finally, Morgan Stanley lifted its position in shares of CRISPR Therapeutics by 18.6% in the 1st quarter. Morgan Stanley now owns 867,268 shares of the company's stock worth $105,678,000 after purchasing an additional 135,841 shares during the period. 55.43% of the stock is currently owned by institutional investors.
Several research analysts have recently commented on the stock. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell raised shares of CRISPR Therapeutics from a "sell" rating to a "neutral" rating and raised their target price for the stock from $55.00 to $132.00 in a report on Monday, June 14th. Jefferies Financial Group raised shares of CRISPR Therapeutics from a "hold" rating to a "buy" rating and set a $172.00 target price on the stock in a research note on Wednesday, April 21st. Citigroup raised shares of CRISPR Therapeutics from a "sell" rating to a "neutral" rating and boosted their target price for the stock from $55.00 to $132.00 in a research note on Monday, June 14th. Evercore ISI upgraded shares of CRISPR Therapeutics to an "outperform" rating in a report on Thursday, May 13th. Finally, JMP Securities began coverage on shares of CRISPR Therapeutics in a report on Thursday, March 4th. They issued an "outperform" rating and a $160.00 target price on the stock. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and fourteen have issued a buy rating to the company's stock. The company presently has a consensus rating of "Buy" and a consensus price target of $158.68.
CRISPR Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA.
Featured Article: Fiduciary
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider CRISPR Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.
While CRISPR Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The 5 Stocks Here